KCSM Newsline November 27, 2014
Found in the blood of all 20 people between the ages of 18 and 50 who were given doses of the vaccine. Nih Officials Say most of the participants had an increase in their immune system tcell count. These cells help to prevent the ebola virus from multiplying inside the human body. No incidents of serious side effects were found. This first phase of the vaccine trial was successful. Now, the next thing is to move to the next phase, which is a much larger trial. He says his team is planning a Clinical Trial of the vaccine in west africa on several thousand people. He says the tests will begin as...
Source: archive.org
